316 related articles for article (PubMed ID: 23280874)
81. Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines.
Kim SK; Ragupathi G; Musselli C; Choi SJ; Park YS; Livingston PO
Vaccine; 1999 Nov; 18(7-8):597-603. PubMed ID: 10547417
[TBL] [Abstract][Full Text] [Related]
82. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity.
Fotin-Mleczek M; Duchardt KM; Lorenz C; Pfeiffer R; Ojkić-Zrna S; Probst J; Kallen KJ
J Immunother; 2011 Jan; 34(1):1-15. PubMed ID: 21150709
[TBL] [Abstract][Full Text] [Related]
83. Design and synthesis of multifunctional gold nanoparticles bearing tumor-associated glycopeptide antigens as potential cancer vaccines.
Brinãs RP; Sundgren A; Sahoo P; Morey S; Rittenhouse-Olson K; Wilding GE; Deng W; Barchi JJ
Bioconjug Chem; 2012 Aug; 23(8):1513-23. PubMed ID: 22812418
[TBL] [Abstract][Full Text] [Related]
84. Potentiating the immune response of MUC1-based antitumor vaccines using a peptide-based nanovector as a promising vaccine adjuvant.
Liu Y; Wang Y; Yu F; Zhang Z; Yang Z; Zhang W; Wang PG; Zhao W
Chem Commun (Camb); 2017 Aug; 53(68):9486-9489. PubMed ID: 28799590
[TBL] [Abstract][Full Text] [Related]
85. Towards a fully synthetic carbohydrate-based anticancer vaccine: synthesis and immunological evaluation of a lipidated glycopeptide containing the tumor-associated tn antigen.
Buskas T; Ingale S; Boons GJ
Angew Chem Int Ed Engl; 2005 Sep; 44(37):5985-8. PubMed ID: 16108081
[No Abstract] [Full Text] [Related]
86. Recent development in carbohydrate-based cancer vaccines.
Guo Z; Wang Q
Curr Opin Chem Biol; 2009 Dec; 13(5-6):608-17. PubMed ID: 19766052
[TBL] [Abstract][Full Text] [Related]
87. Antitumor Humoral and T Cell Responses by Mucin-1 Conjugates of Bacteriophage Qβ in Wild-type Mice.
Yin Z; Wu X; Kaczanowska K; Sungsuwan S; Comellas Aragones M; Pett C; Yu J; Baniel C; Westerlind U; Finn MG; Huang X
ACS Chem Biol; 2018 Jun; 13(6):1668-1676. PubMed ID: 29782143
[TBL] [Abstract][Full Text] [Related]
88. Synthesis of glyco(lipo)peptides by liposome-mediated native chemical ligation.
Ingale S; Buskas T; Boons GJ
Org Lett; 2006 Dec; 8(25):5785-8. PubMed ID: 17134272
[TBL] [Abstract][Full Text] [Related]
89. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses.
Guan HH; Budzynski W; Koganty RR; Krantz MJ; Reddish MA; Rogers JA; Longenecker BM; Samuel J
Bioconjug Chem; 1998; 9(4):451-8. PubMed ID: 9667946
[TBL] [Abstract][Full Text] [Related]
90. A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building.
Zeng W; Horrocks KJ; Robevska G; Wong CY; Azzopardi K; Tauschek M; Robins-Browne RM; Jackson DC
J Biol Chem; 2011 Apr; 286(15):12944-51. PubMed ID: 21321114
[TBL] [Abstract][Full Text] [Related]
91. Influence of conjugation chemistry and B epitope orientation on the immune response of branched peptide antigens.
Monsó M; de la Torre BG; Blanco E; Moreno N; Andreu D
Bioconjug Chem; 2013 Apr; 24(4):578-85. PubMed ID: 23458489
[TBL] [Abstract][Full Text] [Related]
92. Modular platforms for the assembly of self-adjuvanting lipopeptide-based vaccines for use in an out-bred population.
Zeng W; Horrocks KJ; Tan ACL; Wong CY; Chua BY; Jackson DC
Vaccine; 2020 Jan; 38(3):597-607. PubMed ID: 31740096
[TBL] [Abstract][Full Text] [Related]
93. The Adjuvant of α-Galactosylceramide Presented by Gold Nanoparticles Enhances Antitumor Immune Responses of MUC1 Antigen-Based Tumor Vaccines.
Liu Y; Wang Z; Yu F; Li M; Zhu H; Wang K; Meng M; Zhao W
Int J Nanomedicine; 2021; 16():403-420. PubMed ID: 33469292
[TBL] [Abstract][Full Text] [Related]
94. Synthesis and immunological evaluation of self-adjuvanting MUC1-macrophage activating lipopeptide 2 conjugate vaccine candidates.
McDonald DM; Wilkinson BL; Corcilius L; Thaysen-Andersen M; Byrne SN; Payne RJ
Chem Commun (Camb); 2014 Sep; 50(71):10273-6. PubMed ID: 25056269
[TBL] [Abstract][Full Text] [Related]
95. A vision for vaccines built from fully synthetic tumor-associated antigens: from the laboratory to the clinic.
Wilson RM; Danishefsky SJ
J Am Chem Soc; 2013 Oct; 135(39):14462-72. PubMed ID: 23944352
[TBL] [Abstract][Full Text] [Related]
96. Glycopeptide Nanoconjugates Based on Multilayer Self-Assembly as an Antitumor Vaccine.
Liu YF; Sun ZY; Chen PG; Huang ZH; Gao Y; Shi L; Zhao YF; Chen YX; Li YM
Bioconjug Chem; 2015 Aug; 26(8):1439-42. PubMed ID: 26108637
[TBL] [Abstract][Full Text] [Related]
97. Synthesis of MUC1-derived glycopeptide bearing a novel triazole STn analog.
Marchiori MF; Bortot LO; Carvalho I; Campo VL
Carbohydr Res; 2020 Dec; 498():108155. PubMed ID: 33010570
[TBL] [Abstract][Full Text] [Related]
98. Efficient Eradication of Established Tumors in Mice with Cationic Liposome-Based Synthetic Long-Peptide Vaccines.
Varypataki EM; Benne N; Bouwstra J; Jiskoot W; Ossendorp F
Cancer Immunol Res; 2017 Mar; 5(3):222-233. PubMed ID: 28143806
[TBL] [Abstract][Full Text] [Related]
99. Antibody induction directed against the tumor-associated MUC4 glycoprotein.
Cai H; Palitzsch B; Hartmann S; Stergiou N; Kunz H; Schmitt E; Westerlind U
Chembiochem; 2015 Apr; 16(6):959-67. PubMed ID: 25755023
[TBL] [Abstract][Full Text] [Related]
100. Immunology of O-glycosylated proteins: approaches to the design of a MUC1 glycopeptide-based tumor vaccine.
Hanisch FG; Ninkovic T
Curr Protein Pept Sci; 2006 Aug; 7(4):307-15. PubMed ID: 16918445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
